Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise. - Wikidata - wikimedia - TriplyDB

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

http://www.wikidata.org/entity/Q38876402

about

Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer.Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Albumin-Gold Nanorod Nanoplatform for Cell-Mediated Tumoritropic Delivery with Homogenous ChemoDrug Distribution and Enhanced Retention Ability Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases.Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery.Self-assembled albumin nanoparticles for combination therapy in prostate cancer.Förster Resonance Energy Transfer-Based Dual-Modal Theranostic Nanoprobe for In Situ Visualization of Cancer Photothermal Therapy.2D MoS2 Nanostructures for Biomedical Applications.Antigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy.O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia.Regulating the alky chain length of fatty acid-didanosine prodrugs and evaluating its role in albumin binding.Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics.Facile Approach to Synthesize Gold Nanorod@Polyacrylic Acid/Calcium Phosphate Yolk-Shell Nanoparticles for Dual-Mode Imaging and pH/NIR-Responsive Drug Delivery

P2860

Q30840017-56858CCB-C51F-417F-B534-75EE4E84E1E8 Q37682906-2338932A-7D5D-47E5-8E35-B9B2065905DC Q38720819-3CE486CC-9F3D-4BF0-9444-1D0557925CB6 Q38945119-D1C96EE2-8650-42E3-B94B-53625DFFEC68 Q42360027-1A012F21-2E46-40B8-9C17-C715D475B6B8 Q43142557-6DE3B35D-3498-428B-B02D-CCE2F69C1467 Q47101813-EB053D48-6ED7-4597-A4AB-6D90CA1DE479 Q47102130-8DCF4B4A-CE1E-48DA-8E93-09E8B07C2CC5 Q47216721-72873A06-7637-4E83-A7A5-315F33E5E3FA Q48273406-C52C1765-FBB0-424C-8E88-9BFFF5117FB7 Q49788150-6047DBFC-37FA-4865-B3C0-6E00CE4A64CA Q49861125-E9308307-7020-47AB-980D-3462EA3A18B9 Q55024462-333FD355-863E-4548-948A-885CE3B81757 Q58582768-F9D6C145-0009-4F0C-B0CB-D6A0D5947AF0

P2860

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

http://www.wikidata.org/entity/Q38876402

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

@en

type

label

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

@en

prefLabel

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

@en

P1433

Q38876402-D62746C4-34C0-41C3-B08C-8470FDD6BCD3

P1476

Q38876402-0AB24FB3-004D-4B67-8769-AB3FE1FCE131

P2093

Q38876402-367A3A7A-00A6-4AF6-9CA5-1762D6544033

Q38876402-7B1073BE-FB9A-451E-896D-0C389FCD6069

P2860

Q38876402-01FD80F4-B2B1-43BC-A142-CA4153475447

Q38876402-021691DC-D53E-4FB0-A206-E130B3FD3955

Q38876402-02426187-A24B-4CAC-B1F2-4B6143AA54B3

Q38876402-072CD418-3B95-4EAD-93D3-65E990FDE41B

Q38876402-07B5F738-E444-4B74-8890-56C58FE51A94

Q38876402-0A96AF7B-3217-4E52-A1AC-C9112F5DDC6D

Q38876402-0CB2F24A-5C7E-442A-B1A0-205871FB892B

Q38876402-133F9284-55EA-4D48-9670-1D86CF73747C

Q38876402-1525151C-99AF-4CAE-89C3-5AC0FEE1B5D3

Q38876402-1667B077-0ACF-4356-B77C-579778BA4737

P304

Q38876402-8E236088-562B-4964-8693-88DA66DC49D0

P31

Q38876402-6AC59127-88B8-4FCA-ACB0-79E8F9D9C866

P356

Q38876402-5B2F8473-8219-4F6C-9A0B-FC61994B415F

P407

Q38876402-43FFA483-EBE0-421B-8C20-A360EB8E67D3

P433

Q38876402-55E6C4D6-1097-46A9-AE1B-E9EE84F41287

P478

Q38876402-C52757F9-AB83-4331-949E-449C5F46B1E5

P577

Q38876402-1D989603-9CBE-4302-A7CC-B7098AEB5DB0

P698

Q38876402-0F7AEE65-37D9-4FB9-AB24-8A48B3ADAA4A

P356

P1433

Advanced Materials

P1476

Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise.

@en

P2093

Qian Chen

http://www.w3.org/2001/XMLSchema#string

Zhuang Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites

Structural basis of the drug-binding specificity of human serum albumin

Neutrophil-Mediated Delivery of Therapeutic Nanoparticles across Blood Vessel Barrier for Treatment of Inflammation and Infection.

Plasmonic photothermal therapy (PPTT) using gold nanoparticles

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Paclitaxel-HSA interaction. Binding sites on HSA molecule.

Imaging and drug delivery using theranostic nanoparticles

Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer.

A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery.

Photodeposition of silver can result in metal-enhanced fluorescence.

P304

10557-10566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ADMA.201600038

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27111654

http://www.w3.org/2001/XMLSchema#string